» Articles » PMID: 32781490

Minimal Clinically Important Differences in Functional Motor Scores in Adults with Spinal Muscular Atrophy

Overview
Journal Eur J Neurol
Publisher Wiley
Specialty Neurology
Date 2020 Aug 12
PMID 32781490
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: In patients with spinal muscular atrophy (SMA), functional disease scores are frequently used to evaluate the course of the disease and the efficacy of treatment. The aim of the present study was to propose minimal clinically important difference (MCID) values for motor scores in order to estimate the degree of change within a functional score that can be considered clinically meaningful.

Methods: To estimate the MCID, distribution-based approaches were used. For each assessment [Revised Upper Limb Module (RULM), Hammersmith Functional Motor Scale Expanded (HFMSE) and 6-min walk test (6MWT)] and subgroup (SMA type 2, SMA type 3, ambulatory and non-ambulatory), the following MCID values based on a cohort of 51 adults with SMA were calculated: standard error of measurement (SEm), one-half of standard deviation (1/2 SD) and one-third of standard deviation (1/3 SD) of patients' baseline scores.

Results: For the overall cohort, the SEm, 1/2 SD and 1/3 SD MCID values were 2.9, 6.4 and 4.3 for the RULM and 4.3, 10.6 and 7.0 for the HFMSE, respectively. Subgroup analysis led to generally lower standard deviations and consecutively lower MCID values due to the significantly different motor functions of the groups. The respective MCID values for the 6MWT were 55.5 m, 71.1 m and 47.8 m.

Conclusions: Our data provide MCID values for functional motor scores commonly used in adults with SMA in order to distinguish statistical effects from 'real' changes. A complementary systematic consensus process could help to further adjust the MCID values we propose.

Citing Articles

Calculation of the Minimal Clinically Important Difference in Upper and Lower Limb Motor Assessment in Spinal Muscular Atrophy.

Hara T, Miyazaki Y, Shimizu-Motohashi Y, Nishida D, Kamimura A, Takeuchi M Prog Rehabil Med. 2025; 10():20250001.

PMID: 39781427 PMC: 11704608. DOI: 10.2490/prm.20250001.


Risdiplam: therapeutic effects and tolerability in a small cohort of 6 adult type 2 and type 3 SMA patients.

Severa G, Alfaro M, Alimi Ichola C, Shoaito H, Souvannanorath S, Authier F Orphanet J Rare Dis. 2024; 19(1):430.

PMID: 39568039 PMC: 11580475. DOI: 10.1186/s13023-024-03442-0.


Effectiveness of Nusinersen in Adolescents and Adults with Spinal Muscular Atrophy: Systematic Review and Meta-analysis.

Hagenacker T, Maggi L, Coratti G, Youn B, Raynaud S, Paradis A Neurol Ther. 2024; 13(5):1483-1504.

PMID: 39222296 PMC: 11393259. DOI: 10.1007/s40120-024-00653-2.


Patients' Perceptions of Nusinersen Effects According to Their Responder Status.

Lilien C, Vrscaj E, Thapaliya G, Deconinck N, Waele L, Duong T J Clin Med. 2024; 13(12).

PMID: 38929947 PMC: 11205004. DOI: 10.3390/jcm13123418.


Non-Invasive Spinal Cord Stimulation for Motor Rehabilitation of Patients with Spinal Muscular Atrophy Treated with Orphan Drugs.

Novikov A, Maldova M, Shamantseva N, Shalmiev I, Shoshina E, Epoyan N Biomedicines. 2024; 12(6).

PMID: 38927369 PMC: 11200420. DOI: 10.3390/biomedicines12061162.